Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Estrogen receptor beta expression in prostate adenocarcinoma.

Asgari M, Morakabati A.

Diagn Pathol. 2011 Jul 6;6:61. doi: 10.1186/1746-1596-6-61.

2.

The expression and localization of estrogen receptor beta in hyperplastic and neoplastic prostate lesions.

Levakov AF, Kaćanski MM, Vucković N, Zivojinov M, Amidzić J, Sabo JI.

Vojnosanit Pregl. 2015 Oct;72(10):906-13.

PMID:
26665557
3.
4.
5.
6.

High-grade foamy gland prostatic adenocarcinoma on biopsy or transurethral resection: a morphologic study of 55 cases.

Zhao J, Epstein JI.

Am J Surg Pathol. 2009 Apr;33(4):583-90. doi: 10.1097/PAS.0b013e31818a5c6c.

PMID:
19033862
7.

Expression of estrogen receptors alpha and beta, and progesterone receptors A and B in human mucinous carcinoma of the endometrium.

Shabani N, Mylonas I, Jeschke U, Thaqi A, Kuhn C, Puchner T, Friese K.

Anticancer Res. 2007 Jul-Aug;27(4A):2027-33.

8.

Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases.

Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP.

Cancer. 1998 Jun 1;82(11):2256-61.

PMID:
9610707
10.

Analysis of IMP3 expression in prostate adenocarcinomas.

Tosun Yildirim H, Sentürk N.

Turk Patoloji Derg. 2012;28(2):128-33. doi: 10.5146/tjpath.2012.01111.

11.

Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens.

Browne TJ, Hirsch MS, Brodsky G, Welch WR, Loda MF, Rubin MA.

Hum Pathol. 2004 Dec;35(12):1462-8.

PMID:
15619204
12.

Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.

Chuang AY, DeMarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI.

Am J Surg Pathol. 2007 Aug;31(8):1246-55.

PMID:
17667550
13.

p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis.

Parsons JK, Gage WR, Nelson WG, De Marzo AM.

Urology. 2001 Oct;58(4):619-24.

PMID:
11597556
14.
16.

Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker.

Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Young CY, Klee GG, Tindall DJ, Bostwick DG.

Urology. 1997 Jun;49(6):857-62.

PMID:
9187691
17.

Expression of cystatins, high molecular weight cytokeratin, and proliferation markers in prostatic adenocarcinoma and hyperplasia.

Mirtti T, Alanen K, Kallajoki M, Rinne A, Söderström KO.

Prostate. 2003 Mar 1;54(4):290-8.

PMID:
12539227
18.

Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival.

Bostwick DG, Qian J, Pacelli A, Zincke H, Blute M, Bergstralh EJ, Slezak JM, Cheng L.

J Urol. 2002 Sep;168(3):1204-11.

PMID:
12187268
20.

Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies.

Hansel DE, DeMarzo AM, Platz EA, Jadallah S, Hicks J, Epstein JI, Partin AW, Netto GJ.

J Urol. 2007 May;177(5):1736-40.

PMID:
17437801

Supplemental Content

Support Center